Matthew D. Galsky, MD | Authors

Articles

Understanding the Checkpoint Inhibitor-Resistant Disease State

November 11, 2017

Metastatic urothelial cancer is a relatively chemotherapy-sensitive malignancy. With contemporary cisplatin-based combination chemotherapy regimens, objective responses are achieved in approximately 50-60% of patients and complete radiographic responses are achieved in approximately 10-20% of patients.